APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Menstrual Regulating Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Menstrual Regulating Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174012120327 December 2025197 pages

Choose your research edition.

Industry ResearchMenstrual Regulating Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Menstrual Regulating Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Menstrual Regulating Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Menstrual Regulating Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Menstrual Regulating Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Menstrual Regulating Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Menstrual Regulating Drug include Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Pfizer Inc., Bayer AG, AbbVie Inc., Sun Pharmaceutical Industries Ltd. and Sandoz International GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Menstrual Regulating Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Menstrual Regulating Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Menstrual Regulating Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Menstrual Regulating Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Menstrual Regulating Drug Segment by Company

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Merck & Co., Inc.

Mylan N.V.

Pfizer Inc.

Bayer AG

AbbVie Inc.

Sun Pharmaceutical Industries Ltd.

Sandoz International GmbH

Novartis AG

Lupin Limited

HRA Pharma

GlaxoSmithKline plc

Dr. Reddy's Laboratories Ltd.

Allergan plc

Menstrual Regulating Drug Segment by Type

Contraceptive Pills

Non-contraceptive Pills

Menstrual Regulating Drug Segment by Application

Irregular Menstruation

Menstrual Pain

Others

Menstrual Regulating Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Menstrual Regulating Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Menstrual Regulating Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Menstrual Regulating Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Menstrual Regulating Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Menstrual Regulating Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Menstrual Regulating Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Menstrual Regulating Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Menstrual Regulating Drug Industry Trends Table 2. Menstrual Regulating Drug Industry Drivers Table 3. Menstrual Regulating Drug Industry Opportunities and Challenges Table 4. Menstrual Regulating Drug Industry Restraints Table 5. Global Menstrual Regulating Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Menstrual Regulating Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Menstrual Regulating Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Menstrual Regulating Drug Sales Market Share by Manufacturers Table 9. Global Menstrual Regulating Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Menstrual Regulating Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Menstrual Regulating Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Menstrual Regulating Drug Manufacturers, Product Type & Application Table 13. Global Menstrual Regulating Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Menstrual Regulating Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Contraceptive Pills Table 17. Major Manufacturers of Non-contraceptive Pills Table 18. Global Menstrual Regulating Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 20. Global Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 21. Global Menstrual Regulating Drug Sales Market Share by Type (2021-2026) Table 22. Global Menstrual Regulating Drug Sales Market Share by Type (2027-2032) Table 23. Global Menstrual Regulating Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Menstrual Regulating Drug Revenue by Type (2021-2026) & (K Units) Table 25. Global Menstrual Regulating Drug Revenue by Type (2027-2032) & (K Units) Table 26. Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2026) Table 27. Global Menstrual Regulating Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Irregular Menstruation Table 29. Major Manufacturers of Menstrual Pain Table 30. Major Manufacturers of Others Table 31. Global Menstrual Regulating Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 33. Global Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 34. Global Menstrual Regulating Drug Sales Market Share by Application (2021-2026) Table 35. Global Menstrual Regulating Drug Sales Market Share by Application (2027-2032) Table 36. Global Menstrual Regulating Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Menstrual Regulating Drug Revenue by Application (2021-2026) & (K Units) Table 38. Global Menstrual Regulating Drug Revenue by Application (2027-2032) & (K Units) Table 39. Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2026) Table 40. Global Menstrual Regulating Drug Revenue Market Share by Application (2027-2032) Table 41. Global Menstrual Regulating Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Menstrual Regulating Drug Sales by Region (2021-2026) & (K Units) Table 43. Global Menstrual Regulating Drug Sales Market Share by Region (2021-2026) Table 44. Global Menstrual Regulating Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Menstrual Regulating Drug Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 48. North America Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 49. Europe Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 51. Europe Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 58. Global Menstrual Regulating Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Menstrual Regulating Drug Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Menstrual Regulating Drug Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Menstrual Regulating Drug Revenue Market Share by Region (2021-2026) Table 62. Global Menstrual Regulating Drug Revenue Market Share by Region (2027-2032) Table 63. Teva Pharmaceutical Industries Ltd. Company Information Table 64. Teva Pharmaceutical Industries Ltd. Business Overview Table 65. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 67. Teva Pharmaceutical Industries Ltd. Recent Development Table 68. Johnson & Johnson Company Information Table 69. Johnson & Johnson Business Overview Table 70. Johnson & Johnson Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Johnson & Johnson Menstrual Regulating Drug Product Portfolio Table 72. Johnson & Johnson Recent Development Table 73. Merck & Co., Inc. Company Information Table 74. Merck & Co., Inc. Business Overview Table 75. Merck & Co., Inc. Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio Table 77. Merck & Co., Inc. Recent Development Table 78. Mylan N.V. Company Information Table 79. Mylan N.V. Business Overview Table 80. Mylan N.V. Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Mylan N.V. Menstrual Regulating Drug Product Portfolio Table 82. Mylan N.V. Recent Development Table 83. Pfizer Inc. Company Information Table 84. Pfizer Inc. Business Overview Table 85. Pfizer Inc. Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pfizer Inc. Menstrual Regulating Drug Product Portfolio Table 87. Pfizer Inc. Recent Development Table 88. Bayer AG Company Information Table 89. Bayer AG Business Overview Table 90. Bayer AG Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Bayer AG Menstrual Regulating Drug Product Portfolio Table 92. Bayer AG Recent Development Table 93. AbbVie Inc. Company Information Table 94. AbbVie Inc. Business Overview Table 95. AbbVie Inc. Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. AbbVie Inc. Menstrual Regulating Drug Product Portfolio Table 97. AbbVie Inc. Recent Development Table 98. Sun Pharmaceutical Industries Ltd. Company Information Table 99. Sun Pharmaceutical Industries Ltd. Business Overview Table 100. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 102. Sun Pharmaceutical Industries Ltd. Recent Development Table 103. Sandoz International GmbH Company Information Table 104. Sandoz International GmbH Business Overview Table 105. Sandoz International GmbH Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Sandoz International GmbH Menstrual Regulating Drug Product Portfolio Table 107. Sandoz International GmbH Recent Development Table 108. Novartis AG Company Information Table 109. Novartis AG Business Overview Table 110. Novartis AG Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Novartis AG Menstrual Regulating Drug Product Portfolio Table 112. Novartis AG Recent Development Table 113. Lupin Limited Company Information Table 114. Lupin Limited Business Overview Table 115. Lupin Limited Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Lupin Limited Menstrual Regulating Drug Product Portfolio Table 117. Lupin Limited Recent Development Table 118. HRA Pharma Company Information Table 119. HRA Pharma Business Overview Table 120. HRA Pharma Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. HRA Pharma Menstrual Regulating Drug Product Portfolio Table 122. HRA Pharma Recent Development Table 123. GlaxoSmithKline plc Company Information Table 124. GlaxoSmithKline plc Business Overview Table 125. GlaxoSmithKline plc Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio Table 127. GlaxoSmithKline plc Recent Development Table 128. Dr. Reddy's Laboratories Ltd. Company Information Table 129. Dr. Reddy's Laboratories Ltd. Business Overview Table 130. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio Table 132. Dr. Reddy's Laboratories Ltd. Recent Development Table 133. Allergan plc Company Information Table 134. Allergan plc Business Overview Table 135. Allergan plc Menstrual Regulating Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Allergan plc Menstrual Regulating Drug Product Portfolio Table 137. Allergan plc Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Menstrual Regulating Drug Distributors List Table 141. Menstrual Regulating Drug Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Menstrual Regulating Drug Product Image Figure 2. Global Menstrual Regulating Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Menstrual Regulating Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Menstrual Regulating Drug Sales (2021-2032) & (K Units) Figure 5. Global Menstrual Regulating Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Menstrual Regulating Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Contraceptive Pills Image Figure 9. Non-contraceptive Pills Image Figure 10. Global Menstrual Regulating Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Menstrual Regulating Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Menstrual Regulating Drug Sales Market Share by Type (2021-2032) Figure 13. Global Menstrual Regulating Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Menstrual Regulating Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2032) Figure 16. Irregular Menstruation Image Figure 17. Menstrual Pain Image Figure 18. Others Image Figure 19. Global Menstrual Regulating Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Menstrual Regulating Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Menstrual Regulating Drug Sales Market Share by Application (2021-2032) Figure 22. Global Menstrual Regulating Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Menstrual Regulating Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 27. U.S. Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 32. Germany Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 39. China Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 47. Brazil Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Menstrual Regulating Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Menstrual Regulating Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Menstrual Regulating Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Figure 58. North America Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Figure 60. Europe Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Menstrual Regulating Drug Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Menstrual Regulating Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Contraceptive Pills
  • Non-contraceptive Pills
Applications
  • Irregular Menstruation
  • Menstrual Pain
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Novartis AG
  • Lupin Limited
  • HRA Pharma
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Menstrual Regulating Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Menstrual Regulating Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Menstrual Regulating Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Menstrual Regulating Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Menstrual Regulating Drug Market Dynamics
  1. 2.1 Menstrual Regulating Drug Industry Trends
  2. 2.2 Menstrual Regulating Drug Industry Drivers
  3. 2.3 Menstrual Regulating Drug Industry Opportunities and Challenges
  4. 2.4 Menstrual Regulating Drug Industry Restraints
3 Menstrual Regulating Drug Market by Manufacturers
  1. 3.1 Global Menstrual Regulating Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Menstrual Regulating Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Menstrual Regulating Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Menstrual Regulating Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Menstrual Regulating Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Menstrual Regulating Drug Manufacturers, Product Type & Application
  7. 3.7 Global Menstrual Regulating Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Menstrual Regulating Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Menstrual Regulating Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Menstrual Regulating Drug Tier 1, Tier 2, and Tier 3
4 Menstrual Regulating Drug Market by Type
  1. 4.1 Menstrual Regulating Drug Type Introduction
  2. 4.1.1 Contraceptive Pills
  3. 4.1.2 Non-contraceptive Pills
  4. 4.2 Global Menstrual Regulating Drug Sales by Type
  5. 4.2.1 Global Menstrual Regulating Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Menstrual Regulating Drug Sales by Type (2021-2032)
  7. 4.2.3 Global Menstrual Regulating Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global Menstrual Regulating Drug Revenue by Type
  9. 4.3.1 Global Menstrual Regulating Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Menstrual Regulating Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2032)
5 Menstrual Regulating Drug Market by Application
  1. 5.1 Menstrual Regulating Drug Application Introduction
  2. 5.1.1 Irregular Menstruation
  3. 5.1.2 Menstrual Pain
  4. 5.1.3 Others
  5. 5.2 Global Menstrual Regulating Drug Sales by Application
  6. 5.2.1 Global Menstrual Regulating Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Menstrual Regulating Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Menstrual Regulating Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Menstrual Regulating Drug Revenue by Application
  10. 5.3.1 Global Menstrual Regulating Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Menstrual Regulating Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2032)
6 Global Menstrual Regulating Drug Sales by Region
  1. 6.1 Global Menstrual Regulating Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Menstrual Regulating Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Menstrual Regulating Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Menstrual Regulating Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Menstrual Regulating Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Menstrual Regulating Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Menstrual Regulating Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Menstrual Regulating Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Menstrual Regulating Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Menstrual Regulating Drug Revenue by Region
  1. 7.1 Global Menstrual Regulating Drug Revenue by Region
  2. 7.1.1 Global Menstrual Regulating Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Menstrual Regulating Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Menstrual Regulating Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Menstrual Regulating Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Menstrual Regulating Drug Revenue (2021-2032)
  8. 7.2.2 North America Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Menstrual Regulating Drug Revenue (2021-2032)
  11. 7.3.2 Europe Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Menstrual Regulating Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Menstrual Regulating Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Menstrual Regulating Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd.
  2. 8.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Menstrual Regulating Drug Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Mylan N.V.
  20. 8.4.1 Mylan N.V. Company Information
  21. 8.4.2 Mylan N.V. Business Overview
  22. 8.4.3 Mylan N.V. Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan N.V. Menstrual Regulating Drug Product Portfolio
  24. 8.4.5 Mylan N.V. Recent Developments
  25. 8.5 Pfizer Inc.
  26. 8.5.1 Pfizer Inc. Company Information
  27. 8.5.2 Pfizer Inc. Business Overview
  28. 8.5.3 Pfizer Inc. Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. Menstrual Regulating Drug Product Portfolio
  30. 8.5.5 Pfizer Inc. Recent Developments
  31. 8.6 Bayer AG
  32. 8.6.1 Bayer AG Company Information
  33. 8.6.2 Bayer AG Business Overview
  34. 8.6.3 Bayer AG Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer AG Menstrual Regulating Drug Product Portfolio
  36. 8.6.5 Bayer AG Recent Developments
  37. 8.7 AbbVie Inc.
  38. 8.7.1 AbbVie Inc. Company Information
  39. 8.7.2 AbbVie Inc. Business Overview
  40. 8.7.3 AbbVie Inc. Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Inc. Menstrual Regulating Drug Product Portfolio
  42. 8.7.5 AbbVie Inc. Recent Developments
  43. 8.8 Sun Pharmaceutical Industries Ltd.
  44. 8.8.1 Sun Pharmaceutical Industries Ltd. Company Information
  45. 8.8.2 Sun Pharmaceutical Industries Ltd. Business Overview
  46. 8.8.3 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  48. 8.8.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  49. 8.9 Sandoz International GmbH
  50. 8.9.1 Sandoz International GmbH Company Information
  51. 8.9.2 Sandoz International GmbH Business Overview
  52. 8.9.3 Sandoz International GmbH Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sandoz International GmbH Menstrual Regulating Drug Product Portfolio
  54. 8.9.5 Sandoz International GmbH Recent Developments
  55. 8.10 Novartis AG
  56. 8.10.1 Novartis AG Company Information
  57. 8.10.2 Novartis AG Business Overview
  58. 8.10.3 Novartis AG Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis AG Menstrual Regulating Drug Product Portfolio
  60. 8.10.5 Novartis AG Recent Developments
  61. 8.11 Lupin Limited
  62. 8.11.1 Lupin Limited Company Information
  63. 8.11.2 Lupin Limited Business Overview
  64. 8.11.3 Lupin Limited Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lupin Limited Menstrual Regulating Drug Product Portfolio
  66. 8.11.5 Lupin Limited Recent Developments
  67. 8.12 HRA Pharma
  68. 8.12.1 HRA Pharma Company Information
  69. 8.12.2 HRA Pharma Business Overview
  70. 8.12.3 HRA Pharma Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 HRA Pharma Menstrual Regulating Drug Product Portfolio
  72. 8.12.5 HRA Pharma Recent Developments
  73. 8.13 GlaxoSmithKline plc
  74. 8.13.1 GlaxoSmithKline plc Company Information
  75. 8.13.2 GlaxoSmithKline plc Business Overview
  76. 8.13.3 GlaxoSmithKline plc Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio
  78. 8.13.5 GlaxoSmithKline plc Recent Developments
  79. 8.14 Dr. Reddy's Laboratories Ltd.
  80. 8.14.1 Dr. Reddy's Laboratories Ltd. Company Information
  81. 8.14.2 Dr. Reddy's Laboratories Ltd. Business Overview
  82. 8.14.3 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio
  84. 8.14.5 Dr. Reddy's Laboratories Ltd. Recent Developments
  85. 8.15 Allergan plc
  86. 8.15.1 Allergan plc Company Information
  87. 8.15.2 Allergan plc Business Overview
  88. 8.15.3 Allergan plc Menstrual Regulating Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Allergan plc Menstrual Regulating Drug Product Portfolio
  90. 8.15.5 Allergan plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Menstrual Regulating Drug Value Chain Analysis
  2. 9.1.1 Menstrual Regulating Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Menstrual Regulating Drug Production Mode & Process
  6. 9.2 Menstrual Regulating Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Menstrual Regulating Drug Distributors
  9. 9.2.3 Menstrual Regulating Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst